



Check for updates

## METHOD ARTICLE

# Transcriptomic profiling of human skin biopsies in the clinical trial setting: A protocol for high quality RNA extraction from skin tumours [version 1; referees: 2 approved, 1 approved with reservations]

Marina Danilenko<sup>1</sup>, Robert Stones<sup>1</sup>, Neil Rajan <sup>1,2</sup>

<sup>1</sup>Institute of Genetic Medicine, University of Newcastle upon Tyne, Newcastle upon Tyne, NE1 3BZ, UK

<sup>2</sup>Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK

**v1** First published: 23 Apr 2018, 3:45 (doi: [10.12688/wellcomeopenres.14360.1](https://doi.org/10.12688/wellcomeopenres.14360.1))  
Latest published: 23 Apr 2018, 3:45 (doi: [10.12688/wellcomeopenres.14360.1](https://doi.org/10.12688/wellcomeopenres.14360.1))

## Abstract

Transcriptomic profiling of skin disease using next generation sequencing allows for detailed information on aspects of RNA biology including gene expression, non-coding regulatory elements and gene splicing. The application of RNA sequencing to human skin disease and cancer is often hampered by degraded RNA. Here we describe a protocol that allows for consistently intact RNA to be extracted from snap frozen skin biopsy samples, which has been validated in a clinical trial setting.

Human skin tumour punch biopsies (n=28) ranging from 4-6mm in diameter were obtained from 14 patients with an inherited skin tumour syndrome (CYLD cutaneous syndrome) and frozen in liquid nitrogen prior to being stored at -80°C. These samples were then subject to cryostat sectioning, allowing for histological assessment, and were homogenised using a bead-based lysis platform. RNA extraction was performed using a silica column-based system. RNA concentration was measured using fluorescent quantitation and RNA integrity assessed using microfluidic gel electrophoresis. We also processed normal skin biopsies using the same protocol (n=10). The mean RNA integrity score of the tumour and normal samples was 9.5, and the quantity of RNA obtained from the small amounts of tissue used exceeded requirements for RNA-seq library generation.

We propose that the method of RNA extraction suggested here allows for transcriptomic profiling from small pieces of human tissue without the need for PCR amplification during library preparation. This protocol could be utilised in healthy and diseased skin to improve mechanistic understanding in a range of human skin diseases.


## Keywords

Skin biopsy, tumour, CYLD, RNA sequencing, cancer, clinical trial, transcriptomics.

## Open Peer Review

Referee Status: 

	Invited Referees		
	1	2	3
<b>version 1</b>			
published 23 Apr 2018	report	report	report

- Veronica A. Kinsler**, Great Ormond Street Hospital for Children, UK  
UCL Institute of Child Health, UK
- Irene M. Leigh**, Queen Mary University of London, UK
- Verena Wally** , Paracelsus Medical University, Austria  
**Mo Wimmer**, Paracelsus Medical University, Austria

## Discuss this article

[Comments](#) (0)

**Corresponding author:** Neil Rajan ([neil.rajan@ncl.ac.uk](mailto:neil.rajan@ncl.ac.uk))

**Author roles:** **Danilenko M:** Conceptualization, Data Curation, Formal Analysis, Investigation, Resources, Writing – Original Draft Preparation, Writing – Review & Editing; **Stones R:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Rajan N:** Conceptualization, Formal Analysis, Funding Acquisition, Methodology, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**How to cite this article:** Danilenko M, Stones R and Rajan N. **Transcriptomic profiling of human skin biopsies in the clinical trial setting: A protocol for high quality RNA extraction from skin tumours [version 1; referees: 2 approved, 1 approved with reservations]** Wellcome Open Research 2018, 3:45 (doi: [10.12688/wellcomeopenres.14360.1](https://doi.org/10.12688/wellcomeopenres.14360.1))

**Copyright:** © 2018 Danilenko M *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Grant information:** This work was supported by the Wellcome Trust [097163]; Wellcome Trust and Department of Health under the Health Innovation Challenge Fund [100935].

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**First published:** 23 Apr 2018, 3:45 (doi: [10.12688/wellcomeopenres.14360.1](https://doi.org/10.12688/wellcomeopenres.14360.1))

## Introduction

Skin has evolved as a protective barrier against environmental stresses such as physical damage, ultraviolet radiation exposure and pathogenic infections. It is a complex tissue, consisting of many cell types, including keratinocytes, immune cells, melanocytes, fibroblasts, adipocytes, nerve fibres, smooth muscle and endothelial cells (Cole *et al.*, 2001). Skin diseases may involve any of these constituent cells, and transcriptomic profiling of diseased human skin can inform understanding of disease pathogenesis. The accessible nature of the skin, unlike tissues such as the brain or liver, and the low patient impact of skin biopsy, make the use of transcriptomics in human skin particularly attractive. Whole punch biopsies have been studied using transcriptome-wide approaches, giving insights into the inflammatory skin disease psoriasis (Zolotareno *et al.*, 2016).

Reliably obtaining high quality RNA of sufficient quantity from small samples typical of those derived from punch biopsies is, however, problematic. The reasons for this are diverse and include suboptimal tissue disruption and endogenous RNase activity, resulting in skin being a tissue that is amongst the most challenging to obtain intact RNA from (Walker *et al.*, 2016) (Kaufmann *et al.*, 1980). RNA is also a highly unstable molecule. Once extracted from cells or tissues it has a very short half-life and is easily degraded (Brooks, 1998; Tan & Yiap, 2009). RNA is chemically unstable due to the presence of a hydroxyl group at the 2' and thus is highly susceptible to hydrolysis by ribonuclease enzymes. The hydrolysis or cleavage of RNA can also occur spontaneously, without the presence of a catalyst or enzyme (Elliott & Ladomery, 2011). Together, these challenges may discourage the inclusion of transcriptomics in clinical trials involving human skin, where such information may offer mechanistic insights.

Methods of RNA extraction from human skin have been evolving. Early approaches required large amounts of tissue, and were not amenable to medium/high throughput lysis, as each sample had to be disrupted in liquid nitrogen (Hipfel *et al.*, 1998; Kaufmann *et al.*, 1980). Whole punch biopsies of the skin have been successfully disrupted by low throughput devices, such as the Kinematica Polytron 1300D homogenizer and FastPrep120 bead beater (Berglund *et al.*, 2007). 4 mm skin biopsies have also been subjected to ammonium thiocyanate-induced dermo-epidermal separation and subsequently homogenized using bead-based lysis (Clemmensen *et al.*, 2009); however the RNA integrity may have been suboptimal due to tissue processing. Importantly none of these approaches allow for histological assessment of the skin sample, which is relevant in interpreting sequencing results of diseased skin. Laser capture microdissection is an alternative method with histological information, with the limitations being cost of laser capture microscopy equipment, small amount of RNA obtained, and RINs that may be lower (circa 7.0) (Butler *et al.*, 2016). An additional amplification stage is also often required when starting from small amounts of

RNA during library generation, which may introduce an element of bias (Jackson *et al.*, 2014).

Here we report an efficient method of RNA extraction from skin tumours obtained using punch biopsies under local anaesthetic in a clinical trial involving patients with an inherited skin tumour syndrome. We also validated this method in normal human skin biopsies. Downstream analysis demonstrated high yield and RNA integrity, allowing for transcriptomic profiling using RNA sequencing.

## Methods

### Ethics


Regulatory approvals for the present study were sought and obtained from an ethics review committee (National Research Ethics Service Committee North East-Tyne and Wear Ref:14/NE/080 and 06/1059) and the Medicines Health Regulatory authority (EudraCT: 2014-001342-21). Patients provided written, informed consent for biopsy and use of their tissue samples for research. This study used samples collected as part of a clinical trial, registered at ISCRTN 75715723. The study was performed in accordance with the Declaration of Helsinki.

### Sample collection

Tumours scheduled for biopsy as part of the trial protocol were identified using tumour maps and photographs. Tumour identifiers were labelled onto cryovials in advance of the procedure. Skin biopsies were performed under local anaesthetic, and one sample was taken at a time. The biopsy was transferred to a labelled cryovial, with identifiers checked together with a research nurse. The sample was then immediately immersed in liquid nitrogen. All samples were logged in accordance with standard operating procedures and stored in a -80°C freezer within a designated Human Tissue Authority freezer that is subject to temperature monitoring.

### Sample processing

A full working protocol is detailed in [Supplementary File 1](#), and the key steps are outlined here. Standard precautions to prevent contamination with RNases were employed. The sample was removed from the freezer and transferred on dry ice to the cryostat. The sample identifier was used to label slides and preweighed lysis tubes, which were supplied prefilled with beads (Precellys). Skin punch biopsy samples of tumours (4–6 mm diameter) were mounted on a cork piece using cutting compound (OCT), and then serially sectioned ([Figure 1](#)). Each skin biopsy was cryosectioned at two levels and ten 30-micron curls were taken from each level for RNA extraction; two were taken from each biopsy. Sections were then taken for histology and applied to a standard slide, and subject to haematoxylin and eosin staining. Following cryosectioning, material was immediately placed into the bead lysis tube, weighed again and then cold lysis buffer (RLT) containing



**Figure 1. A method for extracting high quality RNA from small skin biopsy samples which is suitable for RNA sequencing.** (a) Diagram indicating key steps in the work flow, and the need to keep samples cold throughout. (A) Human skin punch biopsy (B) Freezing of sample within 30 seconds. (C–D) Cryostat sectioning of punch biopsy and curls obtained. (E–F) Addition of lysis buffer to single use bead tube, followed by homogenisation in the bead-based lysis machine where up to 24 samples can be processed at once. (G) Silica spin column based RNA extraction performed at 4 degrees. (b) Microfluidic gel analysis of total RNA demonstrates distinct 18S and 28S ribosomal bands, consistent with the high RNA integrity scores (c) demonstrated across samples. (d) FASTQC assessment of reads indicate high quality reads in libraries developed from this dataset.

beta-mecaptoethanol was added (Qiagen RNeasy Micro Kit No 74004). The tube was frozen on dry ice and then returned to the -80°C freezer until RNA extraction was performed.

#### RNA extraction and quality control

The protocol supplied with the silica spin column kit (Qiagen RNeasy Micro Kit No 74004, Qiagen UK) was followed with modifications, as indicated in the working protocol (Supplementary File 1). Briefly, bead tubes were taken from the -80°C freezer on dry ice. Tissue was then homogenized in a Precellys Evolution homogeniser (Bertin, France) for 20 seconds at 5500 bpm. After homogenization, the lysate was applied to the column, and then wash steps were performed. On-column DNase digestion was performed for 7 minutes at room temperature. Further washes were performed before RNA was eluted from the column with RNase-free water. All protocol steps were

performed in a cold centrifuge at 4°C at 15000 rpm apart from the DNase incubation step stated above. Eluted RNA was measured using the Qubit BR assay kit (ThermoFisher, UK). RNA quality was measured using a microfluidic gel electrophoresis chip (Bioanalyzer RNA 6000 Nano Chip, Agilent UK). RNA integrity numbers were obtained with the software provided (2100 Expert Software: Revision B.02.09 (SR1)) with the Agilent 2100 Bioanalyser (Agilent, UK) (Schroeder *et al.*, 2006).

#### Transcriptomic analyses

To obtain the cytotokeratin signatures of differentially expressed genes in cylindroma and spiradenoma compared to control skin, three tumour transcript files were compared to three control skin sample files. RNA from each sample was used to generate sequencing libraries using the Illumina Truseq stranded mRNA kit. Libraries were sequenced using an Illumina

HiSeq 2500, giving 45 million paired end reads per sample which were 100 bp in length. FASTQ files were checked for quality using FASTQC and aligned using the splice aware aligner program STAR (v. 2.5.2b) to generate alignment files (Dobin *et al.*, 2013). The read counts for each sample file were obtained using the R package Subread (v.1.28.1) (Liao *et al.*, 2013). Differential gene expression analysis was carried out using DeSeq2 v.1.18.1 (Love *et al.*, 2014). Cytokeratin genes that were differentially expressed with a false discovery rates of <0.05 after correction for multiple hypothesis testing are listed in Table 3.

## Results

### Consistent high-quality RNA is extracted from multiple skin tumours

28 skin biopsies were cryosectioned and material with an average weight of 10.4mg (range 5–14 mg) was obtained at two levels in each biopsy Figure 1a. RNA was obtained from a total of 56 levels, with total yield exceeding the requirements for library preparation for RNA sequencing (yields typically >500ng) in the majority of samples. Sections taken for histology were stained using haematoxylin and eosin, and confirmed adjacent curls were taken from cylindroma and spiradenoma in 25 out of 28 of biopsies; three biopsies demonstrated trichoepithelioma. In 3 out of 56 levels, RNA was not obtained and this correlated with histology reflecting relatively acellular dermis beneath the level of the tumour. The range of concentrations and quality of RNA extracted from tumours are indicated in Table 1 and Figure 1b and c, indicating a mean RIN of 9.5 (range 8.5–10). Control skin sample yields and integrity (mean RIN 9.5; range 8.8–10) are indicated in Table 2.

**Table 1. RNA concentrations and integrity in the 28 skin tumour biopsies studied, with 2 samples taken per biopsy.** Qualitative and quantitative measurements of the total RNA isolated from normal skin punch biopsies.

Tumour	Samples	Concentration (ng/ul)	RNA integrity
1	1	129.6	9.7
	2	17.2	-
2	3	63.2	9.3
	4	too low/undetectable	-
3	5	326	9.3
	6	208	9.3
4	7	118	9.3
	8	76	9
5	9	208	10
	10	142	9.8
6	11	115.6	9.9
	12	29.2	8.5
7	13	272	10
	14	56	10

Tumour	Samples	Concentration (ng/ul)	RNA integrity
8	15	182.8	9.6
	16	169.2	9.6
9	17	147.4	9.5
	18	16.6	-
10	19	99.6	9.4
	20	105.6	9.3
11	21	98	9.5
	22	12.6	-
12	23	41.4	9.1
	24	82.8	9.7
13	25	282	10
	26	228	9.9
14	27	308	9.9
	28	304	10
15	29	258	10
	30	370	10
16	31	800	10
	32	1120	10
17	33	197.8	9.7
	34	244	9.6
18	35	286	9.6
	36	148	9.5
19	37	234	9.4
	38	250	9.6
20	39	362	9.7
	40	254	9.6
21	41	252	10
	42	55	10
22	43	49.6	9.8
	44	26	9.5
23	45	17.2	9.2
	46	21	9.8
24	47	25	8.6
	48	too low/undetectable	-
25	49	360.8	9.7
	50	194.8	9.6
26	51	110.6	9.3
	52	50.6	9
27	53	15.8	8.7
	54	16.6	9
28	55	26.6	8.8
	56	too low/undetectable	-
Average:		180.8	9.5

**Table 2. RNA concentrations and integrity of 10 normal skin samples studied.** Qualitative and quantitative measurements of the total RNA isolated from normal skin punch biopsies.

Samples	Concentration (ng/ul)	RNA Integrity
1	25.2	9.6
2	17	8.8
3	18.6	9.2
4	23	10
5	38.6	9.5
6	20.2	9.5
7	32	9.4
8	36.6	9.4
9	40	9.8
10	21.8	9.7
<b>Average:</b>	<b>27.3</b>	<b>9.5</b>

**Table 3. Expression of known cytokeratin signatures of differentially expressed genes in cylindroma and spiradenoma compared to control skin.**

Gene	log2 Fold Change	Prob. FDR	Description
<i>KRT13</i>	3.94	1.37E-11	Keratin 13
<i>KRT17P2</i>	2.44	0.011702576	Keratin 17 pseudogene 2
<i>KRTCAP3</i>	1.05	0.012251062	Keratinocyte associated protein 3
<i>TCHP</i>	-0.83	0.022666568	Trichoplein keratin filament binding
<i>KRT15</i>	-0.89	0.031124672	Keratin 15
<i>KRT3</i>	-1.56	0.016500418	Keratin 3
<i>KRT9</i>	-1.71	0.002468716	Keratin 9
<i>KRT5</i>	-1.74	0.000610354	Keratin 5
<i>KRT8P26</i>	-1.96	0.012588263	Keratin 8 pseudogene 26
<i>KRT80</i>	-1.96	0.017781638	Keratin 80
<i>KRT19</i>	-2.07	0.035571416	Keratin 19
<i>KPRP</i>	-2.20	0.013678232	Keratinocyte proline rich protein
<i>KRTDAP</i>	-2.35	0.001196344	Keratinocyte differentiation associated protein
<i>KRT78</i>	-2.39	0.00676354	Keratin 78
<i>KRT10</i>	-2.46	0.00126146	Keratin 10
<i>KRT14</i>	-2.48	0.00000538	Keratin 14
<i>KRT1</i>	-2.55	0.000588345	Keratin 1
<i>KRT77</i>	-2.67	0.00000744	Keratin 77
<i>KRT72</i>	-2.71	0.000336864	Keratin 72
<i>KRT27</i>	-2.76	0.005439881	Keratin 27
<i>KRT73</i>	-3.37	3.44E-08	Keratin 73
<i>KRT31</i>	-3.89	4.65E-11	Keratin 31
<i>KRT2</i>	-4.02	0.000000475	Keratin 2



RNA sequencing validates tumour transcriptomic signature  
Reads derived from next generation sequencing were subject to quality control using FASTQc (Figure 1d), and this demonstrated high quality scores, consistent with the high integrity RNA used. Differential gene expression studies focussed on known differentially expressed signature cytokeratin genes in cylindroma and spiradenoma, skin tumours seen in CYLD cutaneous syndrome (Brown *et al.*, 2018). This confirmed that the recognised cytokeratin signature was expressed in these tumour transcriptomes (Table 3).

## Discussion

Due to its high sensitivity and resolution, RNA sequencing is a powerful tool for investigation of skin disease. It can provide mechanistic insights behind disease pathogenesis, which may offer prognostic information, prediction of response to treatments and the potential for developing novel therapies (Gilmore, 2013). To overcome the inherent difficulties of obtaining high integrity RNA, there are in general, four crucial steps required during extraction: cells or tissues should be completely homogenised; nucleoprotein complexes should be disrupted; RNase should be inactivated; contamination including carbohydrate, lipids, protein and other nucleic acid should be avoided (Buckingham & Flaws, 2007; Doyle & Doyle, 1990).

We describe a novel method, incorporating cryostat sectioning, resulting in partial disruption of the tissue, whilst simultaneously allowing us to take 8 µm sections for histological assessment. We used bead-based tubes that allowed for up to 24 samples to be processed simultaneously. Importantly, we were able to work with small amounts of skin, which were robustly disrupted using the bead-based lysis system we employed. This prevented carryover of incompletely homogenised material and obstruction of spin columns used for RNA extraction. The bead-based lysis system we employed had a range of disruption settings and after optimisation with a range of bead sizes, we chose a medium bead mix (CK28 Mix), and lysis of 20 seconds at 5500 rpm in lysis buffer as this gave optimal RNA extraction and RINs.

After skin homogenisation, there are several established methods for RNA extraction. Phenol/chloroform extraction, one of the commonly used techniques, has potential for phenol contamination of the samples, which is often reported (Oñate-Sánchez & Vicente-Carbajosa, 2008). Therefore, we employed a silica column-based RNA extraction methodology (Sellin Jeffries *et al.*, 2014). This approach suited our protocol, which required small volumes of lysis buffer, and elution of RNA performed in 14ul of water. This typically resulted in highly concentrated

samples and thus satisfied the requirements of most RNA library preparation kits for next generation sequencing.

Given RNA's sensitivity to temperature, we developed a protocol where the skin sample is kept as cold as possible throughout. The tumour samples were first snap frozen in liquid nitrogen, and then cryosectioned at a temperature of -20°C. During rapid homogenisation in our protocol, the tumour material was exposed to ambient temperatures for only a few minutes. This was immediately followed by RNA extraction in a precooled centrifuge at 4°C. Spin columns were incubated on wet ice between centrifugation steps and eluted RNA was immediately frozen after RNA extraction was complete.

In summary, we developed a method for efficient extraction of RNA from small cryosectioned pieces of human skin with histological data from adjacent tissue sections. We validated this method in human skin tumours samples in a clinical trial setting. This protocol could be utilised in healthy and diseased skin to improve mechanistic understanding in a range of human skin disease and cancer.

## Data availability

FASTQ files (controls [n=3] and tumours [n=3] used to generate validation signatures), sample description files and uncropped gel images are available at Open Science Framework: <http://doi.org/10.17605/OSF.IO/5YX96> (Rajan, 2018).

Data are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

## Competing interests

No competing interests were disclosed.

## Grant information

This work was supported by the Wellcome Trust [097163]; Wellcome Trust and Department of Health under the Health Innovation Challenge Fund [100935].

*Disclaimer: This publication presents independent research commissioned by the Health Innovation Challenge Fund (HICF-R7-395), a parallel funding partnership between the Wellcome Trust and the Department of Health. The views expressed in this publication are those of the author(s) and not necessarily those of the Wellcome Trust or the Department of Health. The protocol is published to improve the quality of research based on human skin transcriptomics. It is not designed for clinical diagnostic or therapeutic use and is for research applications only. Please ensure all local and national regulatory requirements relating to the relevant use of this protocol are satisfied.*

## Supplementary material

Supplementary File 1: Working protocol.

[Click here to access the data.](#)

## References

- Berglund SR, Schwietert CW, Jones AA, *et al.*: **Optimized methodology for sequential extraction of RNA and protein from small human skin biopsies.** *J Invest Dermatol.* 2007; **127**(2): 349–53.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Brooks G: **Biotechnology in Healthcare : an Introduction to Biopharmaceuticals.** London and Chicago : Pharmaceutical Press, 1998.  
[Reference Source](#)
- Brown SM, Arefi M, Stones R, *et al.*: **Inherited pulmonary cylindromas: Extending the phenotype of CYLD mutation carriers.** *Br J Dermatol.* 2018.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Buckingham L, Flaws M: **Molecular diagnostics : fundamentals, methods, & clinical applications.** 2007.  
[Reference Source](#)
- Butler AE, Matveyenko AV, Kirakossian D, *et al.*: **Recovery of high-quality RNA from laser capture microdissected human and rodent pancreas.** *J Histotechnol.* 2016; **39**(2): 59–65.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Clemmensen A, Thomassen M, Clemmensen O, *et al.*: **Extraction of high-quality epidermal RNA after ammonium thiocyanate-induced dermo-epidermal separation of 4 mm human skin biopsies.** *Exp Dermatol.* 2009; **18**(11): 979–84.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Cole J, Tsou R, Wallace K, *et al.*: **Early gene expression profile of human skin to injury using high-density cDNA microarrays.** *Wound Repair Regen.* 2001; **9**(5): 360–370.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Dobin A, Davis CA, Schlesinger F, *et al.*: **STAR: ultrafast universal RNA-seq aligner.** *Bioinformatics.* 2013; **29**(1): 15–21.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Doyle J, Doyle J: **Isolation of plant DNA from fresh tissue.** *Focus.* 1990; **12**: 13–15.  
[Reference Source](#)
- Elliott D, Ladomery M: **Molecular Biology of RNA.** Oxford University Press. 2011.  
[Reference Source](#)
- Gilmore SJ: **High throughput investigative Dermatology in 2012 and beyond: A new era beckons.** *Australas J Dermatol.* 2013; **54**(1): 1–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hipfel R, Garbe C, Schitteck B: **RNA isolation from human skin tissues for colorimetric differential display.** *J Biochem Biophys Methods.* 1998; **37**(3): 131–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jackson TJ, Spriggs RV, Burgoyne NJ, *et al.*: **Evaluating bias-reducing protocols for RNA sequencing library preparation.** *BMC Genomics.* 2014; **15**(1): 569.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kaufmann R, Belayew A, Nussgens B, *et al.*: **Extraction and translation of collagen mRNA from fetal calf skin.** *Eur J Biochem.* 1980; **106**(2): 593–601.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Liao Y, Smyth GK, Shi W: **The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote.** *Nucleic Acids Res.* 2013; **41**(10): e108.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Love MI, Huber W, Anders S: **Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.** *Genome Biol.* 2014; **15**(12): 550.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Oñate-Sánchez L, Vicente-Carbajosa J: **DNA-free RNA isolation protocols for *Arabidopsis thaliana*, including seeds and siliques.** *BMC Res Notes.* 2008; **1**: 93.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Rajan N: **RNA Seq Data.** *Open Science Framework.* 2018.  
[Data Source](#)
- Schroeder A, Mueller O, Stocker S, *et al.*: **The RIN: an RNA integrity number for assigning integrity values to RNA measurements.** *BMC Mol Biol.* 2006; **7**(1): 3.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sellin Jeffries MK, Kiss AJ, Smith AW, *et al.*: **A comparison of commercially-available automated and manual extraction kits for the isolation of total RNA from small tissue samples.** *BMC Biotechnol.* 2014; **14**(1): 94.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Tan SC, Yip BC: **DNA, RNA, and protein extraction: the past and the present.** *J Biomed Biotechnol.* 2009; **2009**: 574398.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Walker DG, Whetzel AM, Serrano G, *et al.*: **Characterization of RNA isolated from eighteen different human tissues: results from a rapid human autopsy program.** *Cell Tissue Bank.* 2016; **17**(3): 361–75.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zolotarevko A, Chekalin E, Mesentsev A, *et al.*: **Integrated computational approach to the analysis of RNA-seq data reveals new transcriptional regulators of psoriasis.** *Exp Mol Med.* 2016; **48**(11): e268.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)



# Open Peer Review

Current Referee Status: ? ✓ ✓

---

## Version 1

Referee Report 01 June 2018

doi:[10.21956/wellcomeopenres.15623.r33203](https://doi.org/10.21956/wellcomeopenres.15623.r33203)

✓ **Verena Wally** <sup>1</sup>, **Mo Wimmer**<sup>2</sup>

<sup>1</sup> EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria

<sup>2</sup> EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria

The paper "Transcriptomic profiling of human skin biopsies in the clinical trial setting: A protocol for high quality RNA extraction from skin tumours" talks about a novel method to isolate high quality RNA from skin biopsies in a clinical trial setting.

The method is well described and provides information on several aspects to consider in the course of respective sample preparation.

However, we would like to address some points we noticed:

1. Authors state that this is a new method, circumventing several critical aspects of RNA extraction. However, we feel that the novelty is not well enough discussed. A comparison of the key aspects with some aspects of other standard procedures would facilitate a better understanding of the advantages. Optimally, simultaneous RNA preparation with a commonly used method would have been interesting as a methodical control.
2. The problem statement should be elaborated more in detail in the introduction.
3. A statement on why these skin tumours were chosen for the establishment of the method should be included and how patients could benefit from this method in the clinical trial setting.

Minor points:

1. Some more information on the gene expression signature should be given in the text and what relevance the validation of the expression profile has in a clinical trial setting.
2. Table 3: A short statement on the results shown in the table would be helpful in the table description.
3. Figure 1D is not comprehensively described.

4. Why is the final average RNA concentration 10-fold higher in tumour samples compared to normal skin biopsies? (Tables 1 and 2)
5. Table 1. Subtitle: ... is "normal" skin biopsies correct?
6. Some typos / spaces in the paper. (eg. abstract paragraph 2: cYRostat; page 5: **A** false discovery rate**S**, ...)

**Is the rationale for developing the new method (or application) clearly explained?**

Partly

**Is the description of the method technically sound?**

Yes

**Are sufficient details provided to allow replication of the method development and its use by others?**

Yes

**If any results are presented, are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions about the method and its performance adequately supported by the findings presented in the article?**

Yes

**Competing Interests:** No competing interests were disclosed.

**We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Referee Report 24 May 2018

doi:[10.21956/wellcomeopenres.15623.r33121](https://doi.org/10.21956/wellcomeopenres.15623.r33121)



**Irene M. Leigh**

Centre for Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

The results show very good RIN figures by careful attention to detail to inhibit skin RNAases and prevent degradation of RNA etc. The transcriptomic profiling of skin disease for research purposes is well established and it would improve the article to have clarity about the innovative features of this methodology compared to other published studies. The preparation of normal skin has also resulted in very good RIN here but there could be more detail about this. Has the biopsy been treated whole/ fat removed etc? Were the 10 30-micron curls used for normal skin also. Laser capture (discussed) is probably not a competitor for this in skin as heating results in lower RNA integrity. Cylindroma and

trichoepithlioma are very cellular tumours not hyperkeratotic lesions: would this work in much commoner keratotic tumours? Such a method is of course mainly suitable for research studies and clinical trials not for routine pathology labs where transcriptomic profiling is needed on FFPE sections.

**Is the rationale for developing the new method (or application) clearly explained?**

Yes

**Is the description of the method technically sound?**

Yes

**Are sufficient details provided to allow replication of the method development and its use by others?**

Yes

**If any results are presented, are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions about the method and its performance adequately supported by the findings presented in the article?**

Yes

**Competing Interests:** No competing interests were disclosed.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Referee Report 24 April 2018

doi:[10.21956/wellcomeopenres.15623.r32972](https://doi.org/10.21956/wellcomeopenres.15623.r32972)



**Veronica A. Kinsler** <sup>1,2</sup>

<sup>1</sup> Pediatric Dermatology, Great Ormond Street Hospital for Children, London, UK

<sup>2</sup> Genetics and Genomic Medicine, UCL Institute of Child Health, London, UK

Overall this is an excellent contribution to technical knowledge of handling of skin samples, and a well-presented methods paper in so far as the optimised extraction method goes.

I have a few points to be addressed:

1. You are not comparing extraction techniques here, but sample preparation. In this context, there is inadequate information on the handling of the "control" skin samples - detail is needed on how these were taken, how long they were left (and in what?) before extraction. If an RNA stabilisation solution was not used as a comparator this should be addressed, as really this would be the current gold standard for comparison, not direct extraction from a tissue sample that had been left in the fridge or in culture medium. In addition it is not clear whether the normal skin biopsies were also 4-6mm, or whether these were all 4mm.

2. It is possible to divide even a 4mm skin biopsy for histology and RNA extraction and still get enough for a library prep, so the claim that this method is the only one which would allow histology is not correct
3. It is possible that tumours and normal skin differ intrinsically in the amount of RNA produced, and that this is responsible for the differences in quantity, particularly as the quality of the RNA is the same from tumour and normal skin. It would have been much better to use half of each tumour biopsy for each preparation method, and if this could be done on 10 samples going forward you would have a much stronger paper. If not possible in the clinical context this point at least needs to be addressed specifically in the discussion.

**Is the rationale for developing the new method (or application) clearly explained?**

Yes

**Is the description of the method technically sound?**

Partly

**Are sufficient details provided to allow replication of the method development and its use by others?**

Yes

**If any results are presented, are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions about the method and its performance adequately supported by the findings presented in the article?**

Yes

***Competing Interests:*** No competing interests were disclosed.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

---